Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).

Abstract

Scientific evaluation of a patent aiming for the development of pyrazolopyridine derivatives as LRRK2 kinase inhibitors, a potential therapeutic target for combating Parkinson's disease.

• Authors: Xianming Deng, Nathanael S Gray
• Journal: Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 22 Issue 6 Pg. 709-13 (Jun 2012) ISSN: 1744-7674 [Electronic] England
• PMID: 22607035 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antiparkinson Agents
• Protein Kinase Inhibitors
• Pyrazoles
• Pyridines
• pyrazolopyridine
• LRRK2 protein, human
• Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
• Protein Serine-Threonine Kinases

Topics

• Animals
• Antiparkinson Agents (chemistry, pharmacology)
• Drug Design
• Humans
• Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
• Molecular Structure
• Patents as Topic
• Protein Kinase Inhibitors (chemistry, pharmacology)
• Protein Serine-Threonine Kinases (antagonists & inhibitors, metabolism)
• Pyrazoles (chemistry, pharmacology)
• Pyridines (chemistry, pharmacology)
• Structure-Activity Relationship